Skip to content

Author

Matthias Miederer

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Impact of PSMA PET/CT Staging on Long-Term Outcomes in Patients with Clinically Localized Prostate Cancer: Results of a Large Single-Center Cohort.

Prostate-specific membrane antigen (PSMA) PET/CT has become the gold standard for staging and restaging prostate cancer, with superior diagnostic accuracy over conventional imaging and established prognostic value. However, there are limited data on whether PSMA PET/CT-improved staging accuracy is associated with impro...

Sima Esmaeilzadeh Asl, S. Hoberück, A. Sonnenfeld et al. · 0 citations
Open access Aug 2026

Whole-Body MRI Versus 18F-FDG-PET/CT for the Detection of Nodal and Distant Metastases in Pediatric Patients with Solid Tumors

Simple Summary When cancer is diagnosed in a child, it is essential to determine whether it has spread to other parts of the body, because this influences treatment and the chances of recovery. Positron-emission tomography combined with computed tomography is a common diagnostic test that is used for this purpose. Howe...

André Lollert, Maximilian Wittmann, F. Souschek et al. · 0 citations
Open access Sep 2026

PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer.

BACKGROUND AND OBJECTIVE Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) detects distant metastases in more than half of patients with increasing prostate-specific antigen despite castrate levels of testosterone and high-risk nonmetastatic disease on conventional imaging. Here, we aim to eval...

C. Civan, M. Karpinski, C. Darr et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.